GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lee's Pharmaceutical Holdings Ltd (HKSE:00950) » Definitions » Cash Flow from Financing

Lee's Pharmaceutical Holdings (HKSE:00950) Cash Flow from Financing : HK$-2 Mil (TTM As of Dec. 2024)


View and export this data going back to 2002. Start your Free Trial

What is Lee's Pharmaceutical Holdings Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in Dec. 2024, Lee's Pharmaceutical Holdings paid HK$0 Mil more to buy back shares than it received from issuing new shares. It received HK$0 Mil from issuing more debt. It paid HK$0 Mil more to buy back preferred shares than it received from issuing preferred shares. It spent HK$12 Mil paying cash dividends to shareholders. It spent HK$18 Mil on other financial activities. In all, Lee's Pharmaceutical Holdings spent HK$30 Mil on financial activities for the six months ended in Dec. 2024.


Lee's Pharmaceutical Holdings Cash Flow from Financing Historical Data

The historical data trend for Lee's Pharmaceutical Holdings's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lee's Pharmaceutical Holdings Cash Flow from Financing Chart

Lee's Pharmaceutical Holdings Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.80 60.97 -128.60 13.44 -1.96

Lee's Pharmaceutical Holdings Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -78.05 20.74 -7.30 28.00 -29.96

Lee's Pharmaceutical Holdings Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Lee's Pharmaceutical Holdings's Cash from Financing for the fiscal year that ended in Dec. 2024 is calculated as:

Lee's Pharmaceutical Holdings's Cash from Financing for the quarter that ended in Dec. 2024 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lee's Pharmaceutical Holdings  (HKSE:00950) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Lee's Pharmaceutical Holdings's issuance of stock for the six months ended in Dec. 2024 was HK$0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Lee's Pharmaceutical Holdings's repurchase of stock for the six months ended in Dec. 2024 was HK$0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Lee's Pharmaceutical Holdings's net issuance of debt for the six months ended in Dec. 2024 was HK$0 Mil. Lee's Pharmaceutical Holdings received HK$0 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Lee's Pharmaceutical Holdings's net issuance of preferred for the six months ended in Dec. 2024 was HK$0 Mil. Lee's Pharmaceutical Holdings paid HK$0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Lee's Pharmaceutical Holdings's cash flow for dividends for the six months ended in Dec. 2024 was HK$-12 Mil. Lee's Pharmaceutical Holdings spent HK$12 Mil paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Lee's Pharmaceutical Holdings's other financing for the six months ended in Dec. 2024 was HK$-18 Mil. Lee's Pharmaceutical Holdings spent HK$18 Mil on other financial activities.


Lee's Pharmaceutical Holdings Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Lee's Pharmaceutical Holdings's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Lee's Pharmaceutical Holdings Business Description

Traded in Other Exchanges
N/A
Address
Hong Kong Science Park, 1st Floor, Building 20E, Phase 3, Shatin, Hong Kong, HKG
Lee's Pharmaceutical Holdings Ltd is a research-driven and market-oriented biopharmaceutical company. Along with its subsidiaries, it develops, manufactures, sells, and markets pharmaceutical products. It focuses on cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. The company's reportable segments are; Proprietary and generic products which generates key revenue, and Licensed-in products. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase, and Nadroparin Calcium Injection. Its Licensed-in Products include Centraxal Plus, Dicoflor, Ferplex, and Natulan among others. Geographically, the company generates a majority of its revenue from the People's Republic of China.
Executives
Leelalertsuphakun Wanee 2101 Beneficial owner
Lion River I N.v. 2201 Interest of corporation controlled by you
Li Zhenfu 2201 Interest of corporation controlled by you
Assicurazioni Generali Spa 2201 Interest of corporation controlled by you
Huang Zuie-chin 2201 Interest of corporation controlled by you
Lue Shuk Ping Vicky 2202 Interest of your spouse
Li Xiaoyi 2101 Beneficial owner
Lee Siu Fong 2101 Beneficial owner
Ubs Group Ag 2201 Interest of corporation controlled by you
Panacea Venture Healthcare Fund Ii, L.p. 2101 Beneficial owner
Panacea Innovation Limited 2201 Interest of corporation controlled by you
Guang Dong Min Ying Tou Zi Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Apta Finance Sa 2201 Interest of corporation controlled by you
Qualister Sa 2101 Beneficial owner
Paponi Claudia 2202 Interest of your spouse

Lee's Pharmaceutical Holdings Headlines

No Headlines